Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Santiago Grau, Jose Ramon Azanza, Isabel Ruiz, Carlos Vallejo, Josep Mensa, Johan Maertens, Werner J Heinz, Jon Andoni Barrueta, Carmen Peral, Francisco Jesús Mesa, Miguel Barrado, Claudie Charbonneau, Darío Rubio-Rodríguez & Carlos Rubio-Terrés. (2017) Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain. ClinicoEconomics and Outcomes Research 9, pages 39-47.
Read now
Read now
Isabel Sánchez-Ortega, Beatriz Patiño, Carmen Muñoz, Montserrat Arnan, Teresa Peralta, Ana Clopés, Alberto Fernández de Sevilla & Rafael F. Duarte. (2013) Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation. Journal of Medical Economics 16:6, pages 736-743.
Read now
Read now
George Papadopoulos, Sheena Hunt & Manishi Prasad. (2013) Adapting a global cost-effectiveness model to local country requirements: posaconazole case study. Journal of Medical Economics 16:3, pages 374-380.
Read now
Read now
Daoud Al-Badriyeh, Siow Chin Heng, Chin Fen Neoh, Monica Slavin, Kay Stewart & David CM Kong. (2010) Pharmacoeconomics of voriconazole in the management of invasive fungal infections. Expert Review of Pharmacoeconomics & Outcomes Research 10:6, pages 623-636.
Read now
Read now
Carlos Rubio-Terrés & Santiago Grau. (2010) Pharmacoeconomics of voriconazole. Expert Opinion on Pharmacotherapy 11:6, pages 877-887.
Read now
Read now
Kem P Krueger & A Christie Nelson. (2009) Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies. ClinicoEconomics and Outcomes Research 1, pages 35-43.
Read now
Read now
D. Selleslag, D. Vogelaers & S. Marbaix. (2009) ECONOMIC EVALUATION OF VORICONAZOLE VERSUS CASPOFUNGIN FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN BELGIUM. Acta Clinica Belgica 64:5, pages 393-398.
Read now
Read now
Karen Moeremans & Lieven Annemans. (2006) Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients. Expert Opinion on Pharmacotherapy 7:14, pages 1931-1943.
Read now
Read now
Articles from other publishers (14)
L. Drgona, A. Khachatryan, J. Stephens, C. Charbonneau, M. Kantecki, S. Haider & R. Barnes. (2013) Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species. European Journal of Clinical Microbiology & Infectious Diseases 33:1, pages 7-21.
Crossref
Crossref
Me‐Linh Luong, Shahid Husain & Coleman Rotstein. (2013) Pharmacoeconomic assessment of therapy for invasive aspergillosis. Mycoses 56:3, pages 338-349.
Crossref
Crossref
Petros Pechlivanoglou, Robin De Vries, Simon M.G.J. Daenen & Maarten J. Postma. (2011) Cost Benefit and Cost Effectiveness of Antifungal Prophylaxis in Immunocompromised Patients Treated for Haematological Malignancies. PharmacoEconomics 29:9, pages 737-751.
Crossref
Crossref
Jeroen P. Jansen, Amy K. O’Sullivan, Elly Lugtenburg, Lambert F. R. Span, Jeroen J. W. M. Janssen & Wiro B. Stam. (2010) Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands. Annals of Hematology 89:9, pages 919-926.
Crossref
Crossref
D. Al-Badriyeh, D. Liew, K. Stewart & D. C. M. Kong. (2009) Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia. Journal of Antimicrobial Chemotherapy 63:6, pages 1276-1285.
Crossref
Crossref
Wiro B. Stam, Amy K. O’Sullivan, Bart Rijnders, Elly Lugtenburg, Lambert F. R. Span, Jeroen J. W. M. Janssen & Jeroen P. Jansen. (2008) Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. European Journal of Haematology 81:6, pages 467-474.
Crossref
Crossref
A. Atahan Cagatay, F. Cosan, A. Karadeniz, S. K. Besısık, H. Ozsut, M. Nalcaci, Y. Pekcelen, H. Eraksoy, G. Dincol & S. Calangu. (2008) The clinical and pharmacoeconomic analysis of invasive aspergillosis in adult patients with haematological diseases. Mycoses 51:4, pages 328-335.
Crossref
Crossref
E. Romá-Sánchez, J.L. Poveda-Andrés, J. García-Pellicer, M. Salavert-Lletí & I. Jarque-Ramos. (2008) Estudio coste-efectividad de la estrategia empírica antifúngica en pacientes oncohematológicos. Farmacia Hospitalaria 32:1, pages 7-17.
Crossref
Crossref
Hilde Van Campenhout, Sophie Marbaix, Marie-Paule Derde & Lieven Annemans. (2008) Voriconazole Treatment of Invasive Aspergillosis. Clinical Drug Investigation 28:8, pages 509-521.
Crossref
Crossref
Robin de Vries, Simon Daenen, Keith Tolley, Axel Glasmacher, Archie Prentice, Sarah Howells, Hariette Christopherson, Lolkje T W de Jong-van den Berg & Maarten J Postma. (2008) Cost Effectiveness of Itraconazole in the Prophylaxis of Invasive Fungal Infections. PharmacoEconomics 26:1, pages 75-90.
Crossref
Crossref
Eric J. Bow. (2007) Considerations in the approach to invasive fungal infection in patients with haematological malignancies. British Journal of Haematology 140:2, pages 133-152.
Crossref
Crossref
E. Romá-Sánchez, J.L. Poveda-Andrés, J. García-Pellicer, M. Salavert-Lletí & I. Jarque-Ramos. (2008) Cost-Effectiveness Analysis of the Empirical Antifungal Strategy in Oncohaematological Patients. Farmacia Hospitalaria (English Edition) 32:1, pages 7-17.
Crossref
Crossref
Reginald E. Greene, Josephine Mauskopf, Craig S. Roberts, Teresa Zyczynski & Haran T. Schlamm. (2007) Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis. American Journal of Health-System Pharmacy 64:24, pages 2561-2568.
Crossref
Crossref
J.R. Wingard, R. Herbrecht, J. Mauskopf, H.T. Schlamm, A. Marciniak & C.S. Roberts. (2007) Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transplant Infectious Disease 9:3, pages 182-188.
Crossref
Crossref